$SHFH · Scientist Home Future Health Ltd
Scientist Home Future Health Limited filed its 10-Q for the nine months ended September 30, 2026. Q3 revenue exploded 435.3% YoY to $211,984 and the quarter flipped to a slim $8,212 net profit. However, the nine-month picture is grim: net loss of $191,712, cash drained to $13,653, and stockholders' equity turned negative at ($78,205). The auditor includes a going-concern note citing recurring losses, negative operating cash flows, and a working capital deficit.
- Q3 FY2026 revenue hit $211,984, up 435.3% YoY from $39,604, driven by retail trading price increases and volume growth.
- Q3 swung to net income of $8,212 vs. a $47,845 loss in Q3 2025 — the first profitable quarter in the period.
- Nine-month net loss widened to $191,712 from $78,999 YoY as SG&A exploded to $400,909 from $128,297.
- Cash collapsed to $13,653 at September 30, 2026 from $68,888 at year-end 2025; operating cash burn was $129,233.
- Stockholders' equity flipped to a deficit of ($78,205) from positive $113,391 at December 31, 2025, and the auditor flags going-concern risk.
Price data unavailable.
A 435% revenue growth quarter paired with a going-concern warning and negative equity creates an extreme risk/reward profile that demands investor attention.
Micro-cap Hong Kong health-supplement retailer with heavy related-party concentration. The 435% revenue growth is eye-catching but sits alongside a deteriorating balance sheet — a pattern common among small-cap emerging-growth companies scaling unsustainably.
Going-concern warning: recurring operating losses, negative operating cash flows, and a significant working capital deficit. Cash of $13,653 against $424,121 in current liabilities. Nearly all cost of revenues ($275,846 of $275,846 for nine months) flows to a related party, creating acute dependency risk.